New research uncovers key factors driving survival and treatment response in patients with HER2-positive breast cancer ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

编者按：2025年欧洲肿瘤内科学会乳腺癌年会（ESMO ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

Aurobindo Pharma's biosimilar for breast cancer recommended for EU approval, demonstrating similarity to Herceptin.

Hyderabad: CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Limited, has announced that the ...

“With the majority of breast cancer cases historically considered HR positive, HER2 negative, additional treatment options are needed to improve outcomes for patients with metastatic disease ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...